2-methyl-4-(2-phenylethyl)pyridine | 36917-43-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-methyl-4-(2-phenylethyl)pyridine
• 英文别名: 2-methyl-4-phenethylpyridine；2-methyl-4-phenethyl-pyridine
• CAS: 36917-43-8
• 化学式: C₁₄H₁₅N
• 分子量: 197.28
• InChiKey: NRURBTLUGDCSMK-UHFFFAOYSA-N

物化性质

• 沸点：
  292.1±9.0 °C(Predicted)
• 密度：
  1.025±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-4-(2-phenylethyl)pyridine 在 lithium hydroxide 、 正丁基锂 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 为溶剂， 生成 (Z)-2-hydroxy-3-(4-phenethyl-2-pyridyl)prop-2-enoic acid
  参考文献：
  名称：

  A platform for designing HIV integrase inhibitors. Part 1: 2-Hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores

  摘要：

  We present a novel series of HIV integrase inhibitors, showing IC(50)s ranging from 0.01 to over 370 mu M in an enzymatic assay. Furthermore, pharmacophore modeling study for the inhibitors was carried out to elucidate the structure-activity relationships. Finally, we found a 3D-pharmacophorc model, which is composed of a hydrophilic and a hydrophobic domain, providing valuable information for designing other novel types of integrase inhibitors. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.08.044
• 作为产物：
  描述：

  2,4-二甲基吡啶 在 亚磷酸三苯酯 、 甲醇 、 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 25.0h， 生成 2-methyl-4-(2-phenylethyl)pyridine
  参考文献：
  名称：

  Ruthenium-Catalyzed Conversion of sp³ C–O Bonds in Ethers to C–C Bonds Using Triarylboroxines

  摘要：

  Catalytic conversion of unreactive sp(3) C-O bonds in alkyl ethers to C-C bonds is described. Alkyl ethers bearing 2- or 4-pyridyl groups were coupled with triarylboroxines in the presence of a ruthenium catalyst. Triarylboroxines bearing a variety of functional groups including electron-withdrawing and -donating groups can be used for the reaction. No additional base was required for the coupling with the organoboron reagents, and base-sensitive groups can be tolerated. The reaction is considered to proceed via dehydroalkoxylation followed by addition of triarylboroxines to form C-C bonds.

  DOI：

  10.1021/ol2012007

文献信息

• INTEGRASE INHIBITORS CONTAINING AROMATIC HETEROCYCLE DERIVATIVES
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1219607B1

  公开（公告）日：2011-04-06
• US7576198B1
  申请人：——

  公开号：US7576198B1

  公开（公告）日：2009-08-18
• Ruthenium-Catalyzed Conversion of sp³ C–O Bonds in Ethers to C–C Bonds Using Triarylboroxines
  作者：Yohei Ogiwara、Takuya Kochi、Fumitoshi Kakiuchi

  DOI：10.1021/ol2012007

  日期：2011.6.17

  Catalytic conversion of unreactive sp(3) C-O bonds in alkyl ethers to C-C bonds is described. Alkyl ethers bearing 2- or 4-pyridyl groups were coupled with triarylboroxines in the presence of a ruthenium catalyst. Triarylboroxines bearing a variety of functional groups including electron-withdrawing and -donating groups can be used for the reaction. No additional base was required for the coupling with the organoboron reagents, and base-sensitive groups can be tolerated. The reaction is considered to proceed via dehydroalkoxylation followed by addition of triarylboroxines to form C-C bonds.
• A platform for designing HIV integrase inhibitors. Part 1: 2-Hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores
  作者：Takashi Kawasuji、Tomokazu Yoshinaga、Akihiko Sato、Mitsuaki Yodo、Tamio Fujiwara、Ryuichi Kiyama

  DOI：10.1016/j.bmc.2006.08.044

  日期：2006.12

  We present a novel series of HIV integrase inhibitors, showing IC(50)s ranging from 0.01 to over 370 mu M in an enzymatic assay. Furthermore, pharmacophore modeling study for the inhibitors was carried out to elucidate the structure-activity relationships. Finally, we found a 3D-pharmacophorc model, which is composed of a hydrophilic and a hydrophobic domain, providing valuable information for designing other novel types of integrase inhibitors. (c) 2006 Elsevier Ltd. All rights reserved.